Sarcoma Awareness Month: A Rare Cancer That Deserves Attention

A word that covers dozens of diseases

July is Sarcoma Awareness Month. The awareness part is not a formality: most people have never heard the word.

NCI defines soft tissue sarcoma as a broad term for cancers that start in soft tissues, meaning muscle, tendons, fat, lymph and blood vessels, and nerves. They can arise anywhere, but are found mostly in the arms, legs, chest and abdomen.

NCI's health-professional summary gives the distribution: extremities 45 percent, organs inside the abdomen 38 percent, trunk 10 percent, head and neck 5 percent.

This is not one disease. NCI maintains separate treatment summaries for gastrointestinal stromal tumors, Kaposi sarcoma, childhood rhabdomyosarcoma, childhood soft tissue sarcoma and childhood vascular tumors, among others. That range is why sarcoma care is concentrated in specialist centers.

What NCI says about screening, and it is short

There is no screening test.

NCI states that it does not have evidence-based information about screening for soft tissue sarcoma, and does not have evidence-based information about its prevention. On both counts it points readers to its general screening and prevention overviews rather than offering anything sarcoma-specific.

That is an unusual thing for a cancer institute to publish, and it is honest. No routine test finds sarcoma early in people without symptoms. Nothing has been shown to prevent it.

Which means the entire early-detection burden falls on noticing a lump.

When to get checked

NCI puts the sign plainly. A sarcoma may appear as a painless lump under the skin, often on an arm or a leg.

That word painless is the trap. A lump that does not hurt is easy to leave alone.

Sarcomas that start in the abdomen may cause nothing at all until they grow very large. As the tumor presses on nearby organs, nerves, muscles or blood vessels, NCI says the signs can include pain and trouble breathing. Other conditions cause the same things, and NCI advises checking with a doctor.

Size gives a rough handle. NCI's health-professional summary lists a tumor larger than 5 centimeters in greatest dimension among the poor prognostic factors in adults, alongside age over 60, high histological grade, advanced stage at diagnosis, and positive margins after surgery. Five centimeters is about the size of a golf ball.

So the practical prompts are a lump that is growing, a lump bigger than a golf ball, or a lump that came back after removal. Most turn out to be lipomas, cysts or other harmless things. That is why an unfamiliar one is worth showing someone rather than watching for a year. Our page on sarcoma symptoms sets out what an assessment involves.

Why the first biopsy matters more than usual

Here sarcoma differs sharply from most cancers, and it is the most practical thing on this page.

NCI is emphatic on both its patient and professional pages. Tissue should be taken by image-guided core-needle biopsy, or a planned incisional biopsy in selected cases. Because sarcoma is hard to diagnose, the samples should be read by a pathologist experienced in sarcomas.

Then this: careful planning of the biopsy should involve the surgeon, a radiation oncologist and an interventional radiologist together, to avoid compromising later curative removal.

A biopsy takes a track through tissue, and that track can seed tumor cells. Placed badly, it forces a bigger operation later, or makes a limb-sparing one impossible. Incisional biopsies are reserved for cases where a core-needle biopsy was non-diagnostic or cannot be done safely.

Before anything is done, imaging assesses the tumor and looks for spread, using plain x-rays, CT and MRI as needed.

The practical consequence is that a suspected sarcoma is a reason to reach a sarcoma center before the first cut, not after it.

What treatment involves

For stage I disease, NCI lists surgery, surgery with radiation therapy, and high-dose radiation therapy. Chemotherapy is usually not given, because these tumors rarely spread.

The aim in surgery is excision with clear margins of 1 to 2 centimeters or more in all directions. Low-grade sarcomas have little tendency to spread but a real tendency to come back locally, which is what the margin is for.

Higher-grade sarcomas carry higher rates of local treatment failure and greater potential to spread. NCI notes that small low-grade tumors, particularly in the trunk or limbs, are frequently curable by surgery alone. Our page on soft tissue sarcoma covers the later stages.

Follow-up runs long. NCI notes late recurrences more than five years after diagnosis with some types, such as synovial sarcoma and alveolar soft-part sarcoma.

The numbers, and why they are unusual

The American Cancer Society projects 13,910 new US soft tissue cancer cases and 5,400 deaths for 2026, and SEER carries that projection. That is 0.7 percent of all new cancer cases. Median age at diagnosis is 63.

Five-year relative survival for 2016 to 2022 cases is 65.7 percent overall. By spread at diagnosis it is 83.3 percent while confined to the primary site, 58.2 percent with regional lymph nodes involved, and 17.0 percent for distant disease. Fifty-seven percent are found while still localized.

One figure stands out against other cancers. Soft tissue sarcoma takes 3.2 percent of its deaths in people under 20, and another 5.3 percent between 20 and 34. Most adult cancers barely register in those age bands.

These are registry averages across dozens of distinct tumor types with very different behavior. For a group this heterogeneous, an average is a weaker guide than usual, and it describes no individual.

What to keep in perspective

An awareness month cannot substitute for a screening program, because there is not one to promote.

The absence of proven prevention is not a gap in this page. It is what NCI says.

Rarity has consequences beyond statistics. Fewer specialists, fewer trials, longer routes to diagnosis. Our page on sarcoma covers what a specialist referral involves.

And nothing here diagnoses a lump. The point of knowing the features is to lower the threshold for asking, not to sort lumps at home.

Sources

• NCI, Soft Tissue Sarcoma — Patient Version — https://www.cancer.gov/types/soft-tissue-sarcoma
• NCI PDQ, Soft Tissue Sarcoma Treatment (Patient Version) — https://www.cancer.gov/types/soft-tissue-sarcoma/patient/adult-soft-tissue-treatment-pdq
• NCI PDQ, Soft Tissue Sarcoma Treatment (Health Professional Version) — https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq
• SEER Cancer Stat Facts, Soft Tissue including Heart Cancer — https://seer.cancer.gov/statfacts/html/soft.html

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us